Posts in the “Genetic Mutations Genetic Mutations” category:

Data Confirm Anti-ALK Activity in Rare NSCLC

Posted by Samantha Powell on September 27th, 2014 |

Objective responses occurred in 72% of patients with mutation-specific non-small cell lung cancer (NSCLC) treated with crizotinib (Xalkori), final results from a small clinical trial showed. Median response duration approached 1½ years, and median progression-free survival (PFS) had reached 19.2 months with follow-up ongoing. All 50 patients enrolled in the study had chromosomal rearrangements in… Read More

Man Survives Rare Cancer Thanks to New ‘Targeted’ Therapy

Posted by Samantha Powell on September 19th, 2014 |

James “Rocky” Lagno was so sick that doctors only gave him about a year to live. Having been diagnosed with late-stage lung cancer, even aggressive chemotherapy and radiation didn’t prevent the New Hampshire native’s tumors from growing larger. To top it off, he was also diagnosed with thyroid cancer and then, several months later, a… Read More

Lifestyle and genetics strongly impact biomarkers for inflammation and cancer

Posted by Samantha Powell on September 16th, 2014 |

Genetics and lifestyle are determining factors for protein levels in the bloodstream, according to a new study. This discovery greatly influences the possibilities for using more biomarkers to identify disease. This finding came from a large-scale study of the significance of genetic, clinical, and lifestyle factors on protein levels in the bloodstream. It was conducted… Read More

Detecting and Treating ALK-Positive Lung Cancers

Posted by Samantha Powell on August 26th, 2014 |

Hello. This is Mark Kris, from Memorial Sloan Kettering Cancer Center in New York City. I want to spend a few minutes talking about the treatment of ALK-positive lung cancers and ROS1, another of the oncogene fusion-driven lung cancers. We have had some recent data come out. I think the first piece to discuss is… Read More

Gene tests ‘critical’ for diagnosing lung cancer

Posted by Samantha Powell on July 21st, 2014 |

A genetic test is crucial in diagnosing lung cancer as an increasing number of non-smokers in Hong Kong are being afflicted with the disease. A leading respiratory diseases researcher at the University of Hong Kong said this yesterday, noting that 60 per cent of sufferers seen by the university’s department of medicine did not get… Read More

GEOFFREY OXNARD: How Do I Treat Patients with Lung Cancer Harboring EGFR T790M?

Posted by Samantha Powell on July 5th, 2014 |

T790M is a point mutation in the EGFR gene that is associated with resistance to epidermal growth factor receptor (EGFR) kinase inhibitors like erlotinib and gefitinib. Some of the most exciting results presented at this year’s American Society of Clinical Oncology Annual Meeting have to do with new inhibitors targeting the EGFR T790M mutation. Given… Read More

New gene tests may give cancer patients quicker path to treatment

Posted by Samantha Powell on June 6th, 2014 |

A new way of evaluating tumors may soon help cancer patients identify the underlying genetic link to their disease – and the best possible treatment – all in a single test. Researchers are set to begin clinical trials using a more comprehensive testing method that looks for all of the known genes that may be… Read More

The Search for Genes That Prevent Disease

Posted by Samantha Powell on May 29th, 2014 |

What can we learn from people with genetic predispositions to a disease who never end up getting sick? The X-Men’s mutations gave them superpowers. Telepathy. Flight. Teleportation. Some scientists believe that there may be some among us who have a superpower in our genes, too—the ability, against all odds, to stay healthy. Finding these people… Read More

New Data for Gilotrif Shows a Significant Improvement in Overall Survival in Lung Cancer Patients Whose Tumors Have the Most Common EGFR Mutation

Posted by Samantha Powell on May 20th, 2014 |

Date: 5/20/14 Outlet Full Name: Medical News Today Author: No author http://www.medicalnewstoday.com/releases/277021.php Boehringer Ingelheim has announced new overall survival data of two Phase III clinical trials (LUX-Lung 3 and LUX-Lung 6). Patients with advanced non-small cell lung cancer (NSCLC) whose tumors have the most common epidermal growth factor receptor (EGFR) mutation (exon 19 deletion) lived… Read More

Bronchial Gene Test Rules Out Lung Cancer

Posted by Samantha Powell on May 20th, 2014 |

Date: 5/20/14 Outlet Full Name: Med Page Today Author: Crystal Phend http://www.medpagetoday.com/MeetingCoverage/ATS/45872 Gene analysis of the bronchial airway could reduce unnecessary invasive testing for suspected cases of lung cancer, a study suggested. A 17-gene test for normal epithelial cells gathered on bronchoscopy boosted the ability of that procedure to rule out cancer, Duncan Whitney, PhD,… Read More